109 total hip arthroplasty patients were randomized to receive a collagen/thrombin/autologous platelet hemostatic agent in conjunction with standard hemostasis treatment, or standard hemostasis treatment alone, to determine the efficacy of the hemostatic agent on transfusion events. Other outcome measures included perioperative blood loss and narcotic use, postoperative pain and hemoglobin levels, Short Form (SF-12), and (HOOS) scores. Upon analysis, results indicated no significant difference between groups for any of the aforementioned outcomes except postoperative hemoglobin values, which were consistently higher in the hemostatic agent group on days 1,2, and 3 postoperative.